Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
This study has been completed.
Study NCT00061763 Information provided by Novartis
First Received: June 3, 2003 Last Updated: September 21, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Beta-Thalassemia
Myelodysplastic Syndromes
Fanconi Syndrome
Anemia, Diamond-Blackfan
Anemia, Aplastic
Additional conditions recognized in this trial
Anemia
Iron Overload
Preleukemia
Syndrome
Thalassemia
More general conditions related to this trial
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Anemia, Hypoplastic, Congenital
Bone Marrow Diseases
Disease
Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies
Iron Metabolism Disorders
Kidney Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Neoplasms
Pathologic Processes
Precancerous Conditions
Red-Cell Aplasia, Pure
Renal Tubular Transport, Inborn Errors
Urologic Diseases
Interventions listed in this trial
Deferasirox
Additional drug interventions recognized in this trial
Deferoxamine
More general drug interventions related to this trial
Chelating Agents
Iron Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Siderophores
Sponsors listed in this trial
Novartis Pharmaceuticals
Back to top of Main Content
